Company ProfilePremium

Calix Limited

Company Profile Analysis

Ticker: CXL.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Calix Limited - Company showcase

Year Founded & Workforce

2005

108 Employees

Calix Limited logo

Calix Limited Employee Contacts

3 verified contactsNames, job titles, seniority and locations

View Employee Contacts

Calix Limited Overview

MetricFY2024FY2025FY2026
Employees (approx, third-party data)155130108

Note: The FY2024 figure is from Yahoo Finance and FY2026 from Investing.com/S&P. FY2025 (130) is an interpolated placeholder and is not publicly disclosed. Treat the trend as directional only: headcount fell after FY25 restructuring (redundancy payments of A$1.0m in 1H FY25 and A$0.4m in 1H FY26, per Interim Report Note 5).

Calix Limited is an Australian industrial-technology company built around a patented electrically capable, indirectly heated flash-calcination kiln. The kiln separates process CO2 from combustion gases, accepts fine feedstocks and can run on electricity, conventional fuels or hybrids. Commercially, Calix is a two-speed business. Its cash engine is Magnesia: magnesium oxide and hydroxide products for wastewater treatment and aquaculture, made at Bacchus Marsh (Victoria) and sold mainly in North America through subsidiary Inland Environmental Resources. Magnesia delivered A$34.0m of revenue in FY26, up 40%. Around it sits a portfolio of pre-commercial licensing platforms: Leilac (cement and lime carbon capture), Zesty (hydrogen direct-reduced green iron), alumina electrification with Norsk Hydro, lithium mid-stream processing licensed to PLS, and carbon-dioxide removal. In FY26 Calix pivoted to a "capital-light, customer-funded" model after a A$30.2m impairment and Leilac-2 delays. The investment case is a profitable-niche magnesia business plus option value on industrial decarbonisation licensing, constrained by a thin cash position.


Company's own description

In its FY26 results release, Calix calls itself "an industrial technology company transforming the way the world's essential materials are made". It says its patented platform technology is designed to "enable flexible energy use and electric heating, more efficient resource use, and the capture of unavoidable carbon dioxide emissions". It names its target markets as "cement and lime to iron and steel, alumina, critical minerals, water treatment and carbon dioxide removal". (Source: FY26 Results announcement, 26 Aug 2026.)

The 1H FY26 Interim Report lists six claimed technology benefits:

  1. Energy optionality (electricity, conventional or alternative fuels).

  2. Flexible electrification compatible with variable renewables and grid balancing.

  3. Capture of unavoidable process CO2 uncontaminated by combustion gases.

  4. Value-added processing of fines and dust at the mine site.

  5. Minimal hydrogen use in reduction reactions (hydrogen used only as reductant and recyclable).

  6. Highly active, high-surface-area materials from flash heating.

Business model and revenue model

Revenue streamDescriptionWeight (FY26)
Product sales (Magnesia)MgO/Mg(OH)2 slurries and powders for wastewater, biogas, aquaculture; sold under contract and repeat order~94% of product & services revenue (A$34.0m of A$36.0m)
Rental revenueEquipment rental agreements, mostly Magnesia dosing assets<2% (A$0.26m in 1H FY26)
Engineering / technical servicesPaid studies, pre-FEED, material testing (Leilac, Hydro, East Asia cement, Frontier)~A$2.0m combined Leilac + SusPro in FY26 (derived)
Licensing / royaltiesHead licensor of Calix technology; retains 30% of Leilac Group royalties regardless of equity; 20% share of third-party lithium royalties (PLS)Nil material to date
Grants and incentives (other income)ARENA, EU Horizon 2020, Australian Government, UK R&D tax incentivesRecorded as other income (A$1.3m in 1H FY26)

Calix runs a hybrid product-plus-licensing model:

The stated long-term model is "capital-light licensing". Calix develops and demonstrates the technology with partners and grant funding, then licenses it to industrial majors, who fund commercial plants. The 19 Feb 2026 PLS announcement describes the lithium restructure as realigning commercialisation with "Calix's long-term capital-light licensing model".

Value-chain position

Magnesia: Vertically integrated. Calix owns a magnesite (magnesium carbonate) mine at Myrtle Springs, South Australia, calcines at Bacchus Marsh, hydrates in Victoria and Queensland, and runs six North American manufacturing/slurry facilities with direct customer delivery.

Decarbonisation platforms: Technology developer and licensor at the process-equipment and IP layer. It sits upstream of cement, lime, steel, alumina and lithium producers, and alongside EPC firms and equipment OEMs.

Customer types and end markets

End marketCustomer typesStatus
Industrial and municipal wastewater (US, Australia)Food processors, industrial plants, municipal utilitiesCommercial, growing
Aquaculture / lake remediationShrimp farmers, water managersCommercial (smaller)
Cement and limeHeidelberg Materials, Ambuja Cements (Adani), confidential East Asian producer, Titan America, MLC (paused)Pilot / paid engineering
Iron and steelRio Tinto (JDA); Australian Government (ARENA)Demonstration (pre-FID)
AluminaNorsk Hydro (Alunorte refinery, Brazil)Paid pilot testing done Jun 2026
LithiumPLS Group (formerly Pilbara Minerals)Demo plant commissioning; licensed
Carbon dioxide removalFrontier buyers (Google, Stripe, Shopify); DAC (Heirloom exclusivity removed)Paid R&D

Independent characterisation

On FY26 numbers, Calix is economically a ~A$36m-revenue North American wastewater-chemicals business attached to an R&D-heavy decarbonisation venture portfolio. The Magnesia segment has turned profitable at the segment level (1H FY26 segment net profit A$0.6m versus a A$1.9m loss in 1H FY25). Group losses come from Leilac, Sustainable Processing and corporate overhead.

Over FY23–FY25 the company tried to fund demonstration plants directly (Leilac-2, the lithium Mid-Stream UJV). That strategy ended with a A$30.2m write-down of the lithium UJV in 1H FY26 and the de-prioritisation of Leilac-2 in June 2026. The equity market has re-rated the stock accordingly: the price fell from ~A$1.77 (52-week high, early 2026) to A$0.225 by October 2026.

Strategy

Stated strategy (themes from FY26 results and investor communications)

  1. "Capital-light, customer-funded" commercialisation. In the CEO's words, FY26 "marked a shift in Calix's strategy, with a focus on applications that can improve industrial competitiveness today while enabling lower-emissions production over time—prioritising capital-light, customer funded projects."

  2. Grow Magnesia "with a focus on customer service, operational reliability, safety and disciplined expansion" (FY27 priority 1).

  3. Paid test campaigns and customer-funded development in Sustainable Processing (FY27 priority 2).

  4. Advance financing and FID for the Zesty Demonstration Plant (FY27 priority 3), with A$3m of the A$11.4m PLS proceeds reinvested to accelerate Zesty.

  5. Commercialise Leilac through capital-light pathways, prioritising customer-funded projects and partnerships for commercial-scale demonstration (FY27 priority 4).

  6. Platform licensing. Calix acts as head licensor; partners (Rio Tinto, Hydro, PLS, Adani, Heidelberg) fund deployment.

  7. Positioning shift: from "environmental technology" (2025) to "industrial technology" (2026). The FY26 messaging stresses competitiveness (energy-cost savings, hybrid electrification, capacity uplift) alongside decarbonisation, reflecting weaker carbon-policy tailwinds, particularly in the US.

Strategic initiatives (last 24 months)

InitiativeDateDescriptionStatus
FY25 cost-reduction programmeFY25Discontinue non-priority activities, streamline teams; operating cost base down 23% in 2H vs 1H FY25; ~A$8m annualised savingsDelivered; FY26 opex -24%
Capex reductionFY26Cash capex down 80% to A$2.1mDelivered
Lithium Mid-Stream restructureFeb–Jul 2026Exit UJV for A$11.4m; perpetual licence to PLS; 20:80 third-party royalty splitCompleted (both payments received)
Zesty green iron demoJul 2025 onwardARENA up to A$44.9m; Rio Tinto JDA >A$35m; Kwinana siteDetailed design; FID targeted FY27
Alumina electrification (Hydro)Sep 2025 onwardTesting plus pre-FEED >A$1.0m revenuePilot testing completed Jun 2026
Leilac portfolio reprioritisation29 Jun 2026Focus on Ambuja, East Asia and Frontier; de-prioritise Leilac-2, ZETA, US projectsImplemented
Leilac–Ambuja commercial project23 Jun 2026JDA, customer-funded capexEngineering phase
Frontier CDR lime22 Jan 2026Zero-emissions lime for ocean alkalinity enhancementPaid phase due 1H FY27
DAC open licensingJun 2026Heirloom exclusivity removedSeeking new partners
Banking facilityFeb 2026Bank of America facility replacing Columbia Bank line (IER)Executed
US Magnesia expansionDec 2025Contract worth up to A$10m a yearDeliveries from Jan 2026

Guidance and medium-term targets

Guidance itemDetailSource
Cash flowExpects to be cash-flow neutral in CY2026, excluding A$11.4m PLS proceedsFY26 results; 1H FY26 results
RevenueContinued revenue and gross-profit growth in Magnesia (no numerical target)FY26 results
ZestyAdvance financing and FIDFY26 results
CapexMinimal; limited to what Magnesia growth requires (going-concern assumptions)1H FY26 Interim Report
Quantitative medium-term targets (revenue, EBITDA, margin)——

Sustainability commitments

Calix's purpose-led messaging ("Because there's only one Earth. Mars is for quitters.") positions the company's products as decarbonisation enablers.

Products & Services

Magnesia segment

Product / serviceDescription and capabilitiesTarget customerLaunch / statusPricing model
ACTI-Mag (magnesium hydroxide liquid/slurry)Highly active Mg(OH)2 slurry from flash-calcined MgO; raises alkalinity and pH, controls odour/H2S and corrosion, replaces caustic soda in wastewater and biogasMunicipal utilities, food and beverage processors, industrial wastewater, wineriesCommercial for over 10 years; scaled in US via IER from Dec 2019Per-tonne supply contracts and long-term repeat orders; some equipment rental
Magnesium Hydroxide Liquid (MHL) — IER brandUS distribution and manufacture of MHL through six North American facilitiesPacific Northwest and Midwest US industrial and municipal customers (80+ at acquisition)Acquired Dec 2019Supply contracts; new contract with a US customer worth up to A$10m a year (Dec 2025)
AQUA-Cal+Water and pond conditioner for prawn/shrimp aquaculture and lake remediationAquaculture farms, lake managersCommercial (smaller volume)Product sales
Magnesium oxide powdersCalcined MgO from Bacchus Marsh (up to 25,000 tpa)Hydration plants (internal), industrial usersCommercialProduct sales
Dosing and application assets (rental)Slurry manufacturing and application equipment at customer sites (A$13.8m gross "slurry manufacturing and application assets")Wastewater customersOngoingRental agreements (A$0.26m revenue in 1H FY26)
BOOSTER-Mag (legacy)Agricultural crop-protection and yield product (magnesium-based)AgricultureHistorically marketed; capitalised development costs still referenced in 1H FY26 intangibles note; current commercial status not disclosed—

Leilac segment (Leilac Limited)

OfferingDescriptionTarget customerStatus (Oct 2026)
Leilac kiln technology (cement/lime)Indirectly heated calciner retrofitted to cement and lime plants. Process CO2 from limestone stays separate from combustion gases, so it can be captured without chemicals or extra process steps. "Hybrid" heating (fuels and/or electricity). Modular ~100,000 tpa CO2 module design.Cement and lime producersPilot (Leilac-1, 25 ktpa, Lixhe); commercial projects in engineering
Leilac-1Pilot at Heidelberg Materials' Lixhe plant, Belgium; upgraded and retested in FY25R&D / demonstrationOperational pilot
Leilac-2~100,000 tpa CO2 capture demonstration module (EU Horizon 2020 grant of ~€16m); JV with Heidelberg Materials at EnnigerlohHeidelberg MaterialsDe-prioritised (29 Jun 2026): "remains delayed, with no line of sight to a timeline for completion"
Ambuja Cements commercial projectJDA to deploy Leilac at commercial scale at the Sanghi cement plant, Gujarat, India; all capex customer-funded on a "go" decisionAdani Group / Ambuja CementsJDA executed 23 Jun 2026
East Asia cement engineering studyPaid study (up to A$230k) to retrofit Leilac at a cement plant, capture ~100,000 tpa CO2 for local industrial use; capex customer-funded at FIDConfidential East Asian cement producerStudy runs Jul 2026 to 1H FY27
Project ZETAElectric calciner plus CCU for low-emissions lime in South Australia; pre-FEED completed Sep 2025; A$15m Australian Government grant awardedLime producers (SA)Delayed pending matched funding
Zero-emissions lime for CDR (Frontier)Near-zero-emissions lime for ocean alkalinity enhancementFrontier buyers Google, Stripe, ShopifyPaid testing and TEA; completion due 1H FY27
DAC applicationLeilac kilns to regenerate sorbents for direct air capturePreviously Heirloom (Project Cypress); now openHeirloom exclusivity removed Jun 2026
US projects (Titan America, MLC)DOE-selected cement and lime capture projectsUS cement/lime producersPaused; no DOE outcome

Sustainable Processing segment

OfferingDescriptionPartner / customerStatus
Zesty (Zero Emissions Steel TechnologY)Flash hydrogen direct reduction of fine iron ore (H-DRI) in an electrically heated reactor; hydrogen used only as reductant and recycled; targets Pilbara-type fines without pelletisingRio Tinto (JDA, >A$35m value); ARENA (up to A$44.9m)Demonstration plant at Kwinana, WA in detailed design; ARENA milestone 1 paid (A$2m, Mar 2026); Rio first payment A$3m (Dec 2025, booked as SAFE financial liability); further A$5m prepaid tolling fee receivable as the project moves to FID; FID targeted FY27
Lithium Mid-Stream technologyElectric calcination of spodumene concentrate into a higher-value "mid-stream" lithium phosphate/concentrate, reducing transport mass and emissionsPLS GroupDemo plant built (Dec 2025), commissioning from Apr 2026; Calix exited UJV for A$11.4m; PLS has a perpetual royalty-free licence for primary lithium processing; third-party royalties split 20:80 Calix:PLS
Alumina electrificationCalix kiln applied to calcination of alumina hydrate with electric heatingNorsk Hydro (Alunorte, Brazil)Paid pilot-scale testing completed Jun 2026; testing and pre-FEED expected to yield >A$1.0m revenue
Paid material test campaignsCustomer feedstock testing in two electric calciners at Bacchus MarshMiners and processorsOngoing
Legacy: advanced batteriesNano-active battery materials (e.g., lithium manganese oxide) from flash calcinationHistoric R&DNot referenced as active in FY26 disclosures

Financial Narrative

Sources: S&P Global Market Intelligence via StockAnalysis.com (income statement and cash flow updated 25 Aug 2026; balance sheet to 31 Dec 2025); Calix FY26 results release; 1H FY26 Interim Report. A$m unless stated. Fiscal years end 30 June. "Revenue" means product and services revenue, excluding other income (grants).

Income statement

Notes: - FY24 and FY25 pre-tax income includes "earnings from equity investments" (A$12.17m and A$15.07m) — non-cash gains on contribution to the PLS UJV.

  • FY26 pre-tax includes the A$30.3m loss on the UJV (impairment / sale).

  • Company-reported "revenue and other income": FY25 A$33.9m, FY26 A$39.2m (+16%).

  • Company-reported operating costs: FY25 A$39.5m, FY26 A$30.0m (-24%).

  • FY21 reference (S&P): revenue A$19.21m, gross profit A$5.05m, EBIT -A$5.13m, net income -A$7.49m.

Margins

Revenue CAGR:

  • FY22–FY26 (4 years): 18.2%

  • FY21–FY25: 10.0%

  • FY21–FY26 (5 years): (36.02/19.21)^(1/5) − 1 = 13.4%

Half-year progression (A$m): 1H FY25 revenue 13.51, 2H FY25 14.66, 1H FY26 16.32, 2H FY26 19.70 (derived: 36.02 − 16.32). 2H FY26 net loss attributable was approximately A$8.6m (derived: FY26 -51.03 less 1H -42.43), the lowest half-year loss in the recent series.

Commentary.

Inflection: FY26 is the first year that revenue growth (+28%) coincided with an absolute fall in opex (SG&A -14%, R&D -37%). EBIT loss improved by A$14.1m to -A$21.3m, and EBITDA margin halved from -97% to -43%.

Gross margin: Has stabilised around 39–40% after the FY24 peak (42.5%, helped by higher-margin Leilac services revenue). The mix shift to Magnesia (~37–39% segment gross margin) caps blended margin near 40%.

R&D intensity: Peaked at 88% of revenue in FY24 (Leilac-2 engineering, Zesty, lithium) and fell to 31% in FY26 as the company cut non-externally-funded projects.

Reported net loss: Distorted in both directions by UJV accounting: gains of A$12.2m in FY24 and A$15.1m in FY25, then a A$30.3m impairment in FY26. On "EBT excluding unusual items" (S&P), losses were -26.1 (FY24), -19.2 (FY25) and -21.4 (FY26). Underlying FY26 improvement is therefore smaller than the EBIT line suggests, because FY25 EBT benefited from the UJV gain.

Balance sheet

Latest balance sheet points (A$m):

Statutory intangibles of A$12.4m (FY25) include capitalised development costs. S&P splits these between "other intangibles" and "long-term deferred charges". Goodwill (A$3.6m) relates entirely to the 2019 IER acquisition. After the balance date, Calix received a further A$5.7m from PLS on 31 Jul 2026, so pro-forma cash was ~A$15.5m before any other movements.

Commentary. The balance sheet has contracted sharply. Total assets fell 35% in six months to A$72.2m at December 2025, mainly from the A$30.1m PP&E impairment of the Mid-Stream UJV. Net current assets turned negative (-A$2.3m) at 1H FY26, partly because of the A$3m Rio SAFE fee classed as a current financial liability and A$9.1m of deferred grant income. Financial debt is negligible: an asset-finance facility plus a USD500k IER working-capital line, being replaced by a Bank of America facility. The binding constraint is liquidity, not leverage. Cash fell from A$74.5m (FY23) to A$9.8m (FY26) despite a A$20m raise in Dec 2024.

Cash flow

Commentary. FY26 operating cash burn fell 60% to A$11.4m, and 1H FY26 burn was A$6.2m, down 65%. Management guides to cash-flow neutrality in calendar 2026, excluding the A$11.4m PLS proceeds. That depends on continued Magnesia growth, contracted grant milestones (ARENA, Australian Government), UK R&D tax incentives, and the second Rio Tinto JDA payment.

Ratios

Ratio notes: - FY26 ROE, ROIC, current ratio, debt/equity and asset turnover use the latest S&P TTM values (Dec 2025 balance sheet), because the full FY26 balance sheet was not available. FY26 ROA is likewise the S&P TTM figure.

  • ROIC for FY22–FY25 is an approximate analyst estimate (EBIT after nil tax ÷ equity + debt − cash); treat it as indicative.

  • Net debt/EBITDA: Calix is in net cash and EBITDA is negative, so the ratio is economically meaningless. The figures shown are net cash ÷ |EBITDA| (years of EBITDA burn covered by net cash). The FY26 figure is an estimate: ~A$8.8m net cash at Dec 2025 ÷ A$15.56m.

  • Interest coverage is negative in every year (EBIT loss; S&P TTM -106x).

  • Cash conversion cycle (DSO + DIO − DPO on year-end balances) was derived for FY24 (49 days) and FY25 (-16 days) only. Other years are shown as 0 placeholders: not computed / not disclosed.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentContentsKey assets

Magnesia

Magnesium oxide and hydroxide for wastewater (ACTI-Mag / MHL), biogas, aquaculture (AQUA-Cal+) and related uses; formerly the "Water" line of business

Bacchus Marsh commercial calciner (up to 25 ktpa MgO); Myrtle Springs SA magnesite mine; hydration plants in Victoria and Queensland; six North American manufacturing facilities (IER)

Leilac (CO2 mitigation)

Cement and lime carbon capture and electrification; zero-emissions lime for CDR; DAC applications. Held via Leilac Limited (formerly LEILAC Group / Calix (Europe) Ltd), in which Carbon Direct holds a minority interest (6.98% at 2021 entry)

Leilac-1 pilot, Lixhe, Belgium; Leilac-2 JV (Ennigerloh, de-prioritised)

Sustainable Processing (SusPro)

Zesty green iron; lithium mid-stream (until Apr 2026 restructure); alumina (Hydro); other critical minerals; paid material testing

Two electric test calciners at Bacchus Marsh; former 41% share of the Mid-Stream UJV with PLS

Corporate

Group functions, R&D platform, finance, administration

Sydney HQ; Calix Technology Centre laboratory

Revenue by Segment

Segment (AUD Mn)FY2024FY2025FY2026

Magnesia revenue

20.924.334.0

Leilac revenue

3.23.81.0

SusPro revenue

0.10.11.0

Total product and services revenue

24.228.236.0

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Segment Margins & Growth (%) and Revenue by Segment (%)

MetricFY2024FY2025FY2026

Magnesia YoY growth (%)

01640

Magnesia share of product and services revenue (%)

868694

Group product and services revenue growth (%)

301728

Results by Segment

Metric (AUD Mn)1H FY251H FY26

Magnesia revenue

10.6515.75

Magnesia gross profit

4.056.17

Magnesia net profit (loss)

-1.870.64

Leilac revenue

2.860.00

Leilac gross profit

0.81-0.02

Leilac net profit (loss)

-9.27-5.16

SusPro revenue

0.000.56

SusPro gross profit

0.000.54

SusPro net profit (loss)

6.79-30.63

Corporate net profit (loss)

-8.38-7.64

Group net profit (loss)

-12.74-42.79

Margin (%)

Margin (%)1H FY251H FY26

Magnesia gross margin

38.039.1

Magnesia segment net margin

-17.64.1

Group gross margin

36.041.0

Income Statement and Margin Analysis (%)

Metric (AUD Mn)FY2022FY2023FY2024FY2025FY2026

Revenue

18.4718.6024.1928.1736.02

Revenue growth (%)

-3.860.7230.0516.4627.85

Cost of revenue

13.2712.4013.9117.5221.79

Gross profit

5.206.2010.2910.6514.24

SG&A

12.5717.1520.5521.7818.73

R&D expense

7.1014.5321.3817.8211.27

Operating income (EBIT)

-16.68-23.38-38.72-35.39-21.31

EBITDA (S&P)

-12.94-17.87-32.06-27.36-15.56

Pre-tax income

-16.77-23.49-26.29-20.22-51.69

Net income attributable

-16.34-23.19-25.26-19.17-51.03

EPS basic (AUD)

-0.10-0.13-0.14-0.10-0.24

EPS diluted (AUD)

-0.10-0.13-0.14-0.10-0.24

Dividends per share (AUD)

00000

Weighted shares basic (m)

160174182200215

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin (%) (Annual)

Margin (%)FY2022FY2023FY2024FY2025FY2026

Gross margin

28.233.342.537.839.5

Operating (EBIT) margin

-90.3-125.7-160.1-125.6-59.2

EBITDA margin

-70.1-96.1-132.5-97.1-43.2

Net margin

-88.5-124.7-104.4-68.1-141.7

R&D as % of revenue

38.478.188.463.331.3

Balance Sheet and Share Count (m)

Metric (AUD Mn)FY2021FY2022FY2023FY2024FY2025

Total assets

51.6261.21127.51112.40110.38

Cash and equivalents

15.1324.9874.4742.9622.98

Short-term debt incl current leases

0.631.150.681.540.99

Long-term debt incl leases

0.650.340.651.721.64

Total debt (incl leases)

1.291.471.323.262.63

Net debt (negative = net cash)

-14.16-23.71-73.46-40.00-20.62

Total equity

38.1544.80104.9684.0087.55

Goodwill

3.643.643.643.643.64

Other intangibles (S&P classification)

4.764.744.704.644.42

PP&E

15.3219.2425.3943.1060.33

Current assets

27.0231.6189.1152.7231.88

Current liabilities

11.7115.1320.9325.7220.37

Working capital

15.3116.4868.1827.0011.52

Deferred revenue (mainly grants)

6.519.3513.2610.109.64

Shares outstanding (m)

158.55161.50181.18181.92214.75

Financial Analysis

Item30 Jun 202531 Dec 202530 Jun 2026

Cash

22.9811.809.80

Total assets

110.3872.23—

PP&E

57.7431.84—

Intangibles (statutory)

12.4110.42—

Goodwill

3.643.64—

Borrowings

0.140.17—

Rio Tinto SAFE liability

0.003.00—

Total equity

87.5545.90—

Net current assets

11.52-2.33—

“—” = not publicly disclosed.

Cash Flow

Metric (AUD Mn)FY2022FY2023FY2024FY2025FY2026

Operating cash flow

-3.74-17.26-13.68-28.67-11.38

Capital expenditure (S&P, incl UJV share)

-7.44-9.86-15.12-10.28-8.33

Free cash flow

-11.18-27.11-28.79-38.95-19.70

Equity issued

0.8181.59022.090

Dividends paid

00000

Share buybacks

00000

Net change in cash

9.8549.48-31.51-19.98-13.21

Stock-based compensation

0.312.745.132.662.06

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROE (%) — on average equity

-39.4-31.0-26.7-22.3-72.9

ROA (%) — on average assets

-29.0-24.6-21.1-17.2-17.2

ROIC (%) — S&P

-35.0-28.0-30.0-25.0-22.7

Current ratio (x)

2.094.262.051.570.90

Debt / equity (x, incl leases)

0.030.010.040.030.07

Net debt / EBITDA (x)

1.834.111.250.750.57

Asset turnover (x)

0.330.200.200.250.33

Cash conversion cycle (days, derived)

0049-160

Revenue by Region

Region (AUD Mn)1H FY251H FY26

APAC including Australia

2.174.61

EMEA

0.000.00

Americas

11.3511.70

Total

13.5116.32

Region growth and share (%)

Region growth and share (%)1H FY251H FY26

APAC YoY growth (%)

0112.8

Americas YoY growth (%)

03.2

APAC share of revenue (%)

16.028.3

Americas share of revenue (%)

84.071.7

Segment Overview — Magnesia

SegmentAPACEMEAAmericasTotal

Magnesia

4.450.0011.3115.75

Leilac

0.000.000.000.00

SusPro

0.170.000.400.56

Total

4.610.0011.7016.32

Segment × geography (1H FY25, AUD Mn)

APAC

EMEA

Americas

Total

Magnesia

2.010.008.6510.65

Leilac

0.160.002.702.86

SusPro

0.000.000.000.00

Total

2.170.0011.3513.51

Capital Markets

MeasureValueSource / note

Last price (8 Oct 2026)

A$0.225

StockAnalysis

52-week high

~A$1.77

SmallCaps (early 2026)

52-week low

~A$0.225 (current)

Derived

Price at FY26 results (26 Aug 2026)

A$0.30 at release; ~A$0.23 after

InvestSMART

1-year change (from ~A$0.47–0.49, Oct 2025)

approx -53%

InvestSMART release prices

Beta (5Y)

0.75

S&P

Average daily volume (20-day, Aug 2026)

~345,000 shares

S&P

Share Price

Price point (AUD)Nov 2025Dec 2025Feb 2026Mar 2026Jun 2026Aug 2026Oct 2026

Share price at key releases

0.4650.5151.590.750.4250.300.225

Valuation Multiples

MultipleCalix (approx, 8 Oct 2026)Basis

Market cap

A$48.6m

215.8m × A$0.225

Enterprise value

~A$36m

Market cap − ~A$15.5m pro-forma cash (A$9.8m + A$5.7m PLS) + ~A$3m debt and leases (estimate)

EV / Sales (FY26)

~1.0x

A$36m ÷ A$36.0m

P / Sales (FY26)

~1.35x

A$48.6m ÷ A$36.0m

P / E

n/m (loss-making)

—

EV / EBITDA

n/m (negative EBITDA)

—

P / B

~1.06x on 1H FY26 book (A$45.9m); FY26 book not disclosed in sources reviewed

—

Capital Markets — Dividend policy

ItemDetail

Dividend policy

No dividends paid as a listed company; none expected while loss-making. (InvestSMART shows legacy 2004–2005 dividends for the CXL code, likely from a prior entity on that ticker.)

Buybacks

None authorised

Credit ratings (Moody's / S&P / Fitch)

None — unrated

Debt maturity profile

Negligible: asset-finance facilities (A$0.16m current), lease liabilities (~A$3.1m, current A$1.0m), Bank of America facility (size not disclosed)

Equity raised (AUD Mn)

Equity raised (AUD Mn)FY2022FY2023FY2024FY2025FY2026

Common stock issued (cash)

0.8181.59022.090

Analyst Conclusions

Management guidance

  • Cash-flow neutral in calendar 2026, excluding the A$11.4m PLS proceeds.

  • Continued Magnesia revenue and gross-profit growth.

  • Progress paid test campaigns in SusPro.

  • Advance financing and FID for the Zesty demo.

  • Commercialise Leilac through capital-light, customer-funded projects.

  • A$3m of PLS proceeds reinvested in Zesty.

Consensus expectations

S&P shows a 3-year revenue growth forecast of ~24.5% a year. No published EBITDA or EPS consensus was identified. Coverage is thin (two brokers) and targets appear stale.

Bull case

  1. Magnesia becomes a scaled, cash-generative core. FY26 revenue was A$34.0m (+40%) with the up-to-A$10m-a-year US contract only partly reflected. Annualising 2H FY26 group revenue (~A$19.7m per half) implies ~A$39–45m in FY27. At ~40% gross margin and a A$30m opex base trending down, group EBITDA breakeven is within reach.

  2. Customer-funded Leilac deployments re-rate the platform. A "go" decision at Ambuja's Sanghi plant or the East Asian plant would deliver Leilac's first commercial cement plant without Calix capital, monetised through engineering fees and royalties (Calix keeps 30% of Leilac royalties).

  3. Zesty FID crystallises value. Rio Tinto (>A$35m) and ARENA (A$42.9m remaining) would fund a green-iron demo with a mining major. Project-level equity (SAFE conversion) could reveal a valuation well above the current ~A$36m group EV.

Bear case

  1. Liquidity squeeze forces a dilutive raise. Cash was A$9.8m at FY26 (~A$15.5m pro-forma). Neutrality depends on milestone-linked inflows (Rio's second payment, ARENA, UK R&D incentives), and any slippage means raising equity at a depressed price.

  2. Repeated failure to reach commercial scale. Leilac has been in pilot since 2019. Leilac-2 is shelved, ZETA is unfunded and the US projects are paused. The lithium exit crystallised a A$30.2m loss, which suggests the platform's economics are hard to prove at scale.

  3. Magnesia alone does not justify the cost base. Even a profitable A$40m magnesia business, valued as a niche specialty chemical, may not support a structure carrying ~A$15m of corporate and R&D cost unless licensing revenue materialises.

Key catalysts and monitorables (next 12 months)

CatalystExpected timingWatch for
FY26 Annual Report and 2026 AGMOct–Nov 2026Remuneration vote, FY26 balance sheet, segment detail, going-concern wording
Magnesia quarterly run-rate and US contract rampOngoing; 1H FY27 results Feb 2027Revenue per half above A$20m; gross margin at or above 40%
CY2026 cash-flow neutralityDec 2026 / Feb 2027 reportCash at 31 Dec 2026 versus ~A$15.5m pro-forma
Zesty financing and FIDFY27Third-party equity, Rio second payment, ARENA milestones
East Asia engineering study completion1H FY27Progression to FEED or FID
Ambuja "go" decisionFY27 or laterCommercial terms, royalty structure
Frontier CDR phase completion1H FY27Follow-on offtake or contracts
Hydro pre-FEEDFY27Path to licence
Leilac-2 consortium alternative planUncertainRestructuring or termination; grant implications
Capital raisingAny timeSize, price, investor support (AustralianSuper, Thorney/TIGA)

Concluding analyst verdict

Calix enters FY27 as a smaller, more disciplined and far less valued company than it was eighteen months ago. FY26 confirmed two things.

First, the Magnesia business is real. Revenue rose 40% to A$34.0m at a ~37–40% gross margin, the segment is now profitable, and it has a contracted growth leg in the US. That business alone plausibly supports a meaningful part of today's ~A$49m market capitalisation.

Second, the strategy of funding first-of-a-kind decarbonisation plants on Calix's own balance sheet has failed financially, even where execution was competent. The lithium Mid-Stream plant was built on budget, yet Calix exited at a A$30.2m impairment. Leilac-2 is shelved after the Hanover relocation and European demand weakness, and US federal funding has disappeared.

Management's pivot to a capital-light, customer-funded model is the correct response, and it is supported by unusually strong counterparties: Rio Tinto, Norsk Hydro, Adani/Ambuja and Frontier's corporate buyers. Cost cuts are real: opex fell 24%, cash capex 80% and operating burn 60%.

The pivot does have a price. Calix now depends on partners' timetables and milestone-based payments to stay solvent, with only ~A$15.5m of pro-forma liquidity. The market is pricing this as a distressed option: EV of about 1x sales, roughly at book value, with negligible credit given to Leilac or Zesty.

Our view is that CXL is a high-risk, special-situation holding. Its value rests on (1) achieving the CY2026 cash-neutral target without a deeply dilutive raise and (2) at least one customer-funded commercial decision (Ambuja, East Asia or a Zesty FID) within 12–18 months. Delivery on both would make today's valuation look anomalously low against the Magnesia earnings stream alone. A missed cash target or a stalled Zesty financing would likely force equity issuance at or below current levels. Position sizing should reflect binary outcomes, and investors should track half-year cash balances above all other metrics.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleAppointedBackground / educationIndependence

Alison (Catriona) Deans

Non-Executive Chair

Director Mar 2023; Chair from 1 Oct 2024

Former CEO of eBay ANZ, eCorp, Hoyts Cinemas and netus; ex-McKinsey; Chair of Cochlear; NED of Ramsay Health Care; former NED of Westpac and IAG; Investment Committee, Main Sequence Ventures

Independent

Dr Phil Hodgson

Managing Director & CEO

CEO since Jan 2013

BE, PhD; prior commercial and technical roles at Shell

Executive

Helen Fisher

Non-Executive Director

——

Independent (presumed)

Dr Sarah Ryan

Non-Executive Director

2024 (casual vacancy; elected at 2024 AGM)

—

Independent (presumed)

Peter Dixon

Non-Executive Director

2024 (casual vacancy; elected at 2024 AGM)

—

Independent (presumed)

“—” = not publicly disclosed.

Executive Leadership Team

NameTitleNotes

Dr Phil Hodgson

MD & CEO

CEO since 2013; holds ~2.3% of shares (~4.9m)

Darren Charles

CFO & Company Secretary

B Com, FCPA

Daniel Rennie

CEO, Leilac Group

Leads Leilac since its 2021 stand-alone structure

Dr Matt Boot-Handford

Chief Scientist

Succeeded Sceats in the scientific lead role

Dr Mark Sceats

Co-Founder & Emeritus Chief Scientist

~3.6% holder

Simon Thomsen

Chief Technology Officer

—

Michelle Bennett

Chief Engineering & Projects Officer

—

Helen Comerford

Chief People & Culture Officer

—

Dr Doug Kelley

GM Water (North America) & President, IER

—

Andrew Okely

GM Commercial

—

Vincent Nguyen

GM Operations

—

Christineh Grigorian

Investor Relations Manager

—

Directors' Remuneration

PersonYearSalary (AUD K)Variable / equity (AUD K)Total (AUD K)Source

Phil Hodgson (CEO)

FY25

463110573

Simply Wall St (from FY25 remuneration report)

Phil Hodgson

Earlier (Yahoo)

——520

Yahoo Finance

Darren Charles (CFO)

Earlier (Yahoo)

——380

Yahoo Finance

Daniel Rennie (Leilac CEO)

Earlier (Yahoo)

——392

Yahoo Finance

Doug Kelley (IER)

Earlier (Yahoo)

——390

Yahoo Finance

Board & Management Changes

DateChange

30 Sep 2024

Peter Turnbull AM retires as Chair (Chair since the 2018 listing; associated with Calix since about 2009)

1 Oct 2024

Alison Deans becomes Chair

2024

Peter Dixon and Dr Sarah Ryan appointed to fill casual vacancies

FY25

Streamlining of teams under the cost-reduction programme

Major Shareholders

HolderShares (m)Stake (%)TypeSource / date

AustralianSuper Pty Ltd

37.4317.4

Institution (superannuation)

Simply Wall St (2025–26)

TIGA Trading Pty Ltd (Thorney group)

17.328.1

Institution / family office

Simply Wall St

Nicholas Merriman

10.975.1

Individual

Simply Wall St

Mark Sceats (co-founder)

7.763.6

Insider

Simply Wall St

Paul Crowther

5.392.5

Individual

Simply Wall St

Phil Hodgson (CEO)

4.922.3

Insider

Simply Wall St

Thorney Technologies Ltd

4.692.2

Institution (listed investment co)

Simply Wall St

Handelsbanken Asset Management

4.091.9

Institution

Simply Wall St

Fidelity International

~1.9

0.9

Institution

Simply Wall St

Competitive Landscape

Competitors by Segment

SegmentCompetitorTypeRelative positioning vs Calix

Magnesia (US wastewater Mg(OH)2)

Martin Marietta Magnesia Specialties (US)

Division of a large-cap aggregates company

Larger, integrated US magnesia producer; scale advantage

Magnesia

Premier Magnesia (US)

Private

Established US Mg(OH)2 slurry supplier; direct head-to-head

Magnesia

Huber Engineered Materials / other Mg(OH)2 suppliers

Private / large chemical

Broad product range

Magnesia

Caustic soda and lime suppliers (e.g., Olin, OxyChem, Carmeuse, Lhoist)

Substitute chemistries

Calix sells Mg(OH)2 as a safer, buffering alternative to caustic

Magnesia (Australia)

Queensland Magnesia (QMAG; RHI Magnesita group)

Global refractory major

Upstream magnesia supplier; competes in some industrial grades

Leilac (cement capture)

SLB Capturi (ex-Aker Carbon Capture)

Amine capture

Commercial-scale reference at Heidelberg Brevik (Norway); higher energy penalty but proven

Leilac

Mitsubishi Heavy Industries (KM CDR)

Amine capture

Large-cap, global references in power and industry

Leilac

thyssenkrupp Polysius (oxyfuel / "pure oxyfuel")

Oxyfuel kilns

Direct alternative for kiln process CO2; OEM incumbency

Leilac

FLSmidth Cement (now Pacific Avenue Capital)

Kiln OEM

Incumbent kiln supplier; electrification R&D

Leilac

Air Liquide (Cryocap), Linde

Cryogenic / gas-separation capture

Industrial-gas majors with project-delivery capacity

Leilac / electrification

Coolbrook (RotoDynamic Heater)

Electrified high-temperature heat

Competes on electrification thesis

CDR lime / DAC

Origen (zero-emission lime), Heirloom (now non-exclusive), Climeworks

CDR developers

Compete for Frontier-type offtake capital

Zesty (green iron)

Midrex (Kobe Steel), Energiron (Tenova / Danieli), HYFOR (Primetals), HYBRIT

H-DRI / fines reduction

Midrex and Energiron dominate DRI; HYFOR targets fines like Zesty

Zesty

Boston Metal, Electra

Electrochemical iron

Alternative green-iron routes

Alumina electrification

Alcoa (mechanical vapour recompression, electric calcination R&D), Rio Tinto internal programmes

Incumbent producers

Producers may build in-house solutions

Lithium mid-stream

Conventional rotary-kiln spodumene conversion (Chinese converters)

Incumbent process

Calix offers on-site electric calcination

Peer Comparison FY2026

MetricCalix (FY26)SLB CapturiMidrex (Kobe Steel)

Revenue

A$36.0m

——

Revenue growth

+28%——

Gross margin

39.5%——

R&D intensity

31% of revenue

——

Commercial reference plants in core decarbonisation tech

0 (pilot only)

≥1 cement (Brevik)

~100 DRI modules (gas-based)

“—” = not publicly disclosed.

Recent Developments

Layoffs: * FY25 headcount reductions (redundancies A$1.0m in 1H FY25; A$0.36m in 1H FY26).

Company Snapshot

$23.2M

Revenue

108

Employees

2005

Founded

Sydney, Australia

Headquarters

SWOT Analysis

Strengths

  • Growing, now-profitable Magnesia business: FY26 Magnesia revenue A$34.0m (+40%), gross profit A$12.6m (+31%); 1H FY26 segment net profit A$0.6m versus a A$1.9m loss (FY26 results; Interim Note 2).
  • Operating cost discipline: FY26 operating costs down 24% to A$30.0m; operating cash outflow down 60% to A$11.4m (FY26 results).
  • Blue-chip partner validation: Rio Tinto JDA (>A$35m), Hydro, Ambuja (Adani), PLS licence, Frontier buyers (Google, Stripe, Shopify).
  • Large non-dilutive funding: ARENA up to A$44.9m (A$42.9m still to come), A$15m Australian Government ZETA grant, EU Horizon 2020 for Leilac-2.
  • Vertical integration in Magnesia: owned Myrtle Springs mine, Bacchus Marsh calciner (25 ktpa) and six US manufacturing sites (Interim Report).
  • Low financial leverage: total borrowings A$0.17m at Dec 2025; debt/equity ~0.07x including leases.
  • Retained royalty economics: 30% of Leilac royalties regardless of equity; 20% of third-party lithium royalties.

Weaknesses

  • Persistent losses: FY26 net loss A$51.0m (including A$30.3m impairment); EBIT loss A$21.3m; nine consecutive loss years in the S&P series.
  • Thin liquidity: cash A$9.8m at 30 Jun 2026 (from A$74.5m in FY23); net current assets -A$2.3m at Dec 2025.
  • Failed capital-heavy demonstrations: A$30.2m write-down on the lithium UJV; Leilac-2 delayed with "no line of sight" to completion (29 Jun 2026).
  • Revenue concentration: ~94% of product and services revenue from one segment; ~72% from the Americas (1H FY26).
  • No commercial-scale reference for Leilac after the 2019 pilot start.
  • Shareholder dilution: shares rose from 158.6m (FY21) to ~215.8m (2026), +36%; YoY change +16.6% (S&P).

Opportunities

  • US Magnesia contract ramp: up to A$10m a year (Dec 2025); full-year contribution in FY27.
  • Customer-funded Leilac deployments in Asia: Ambuja (Sanghi, Gujarat) and East Asia (~100 ktpa CO2); no Calix capex required.
  • Zesty FID in FY27, unlocking ARENA and Rio Tinto funding plus a potential project-level equity partner.
  • Alumina electrification with Hydro: the paid pilot is done; pre-FEED could lead to commercial licensing.
  • Open DAC licensing after the Heirloom exclusivity ended (Jun 2026).
  • EU CBAM and ETS tightening (2026 onward) should improve European cement-capture economics.

Threats

  • US policy reversal: DOE funding reviews paused the Titan America, MLC and Project Cypress projects.
  • European construction weakness: the Heidelberg Hanover closure (Jan 2024) caused the Leilac-2 relocation and delays.
  • Competing capture technologies with commercial references (SLB Capturi at Brevik; oxyfuel from Polysius).
  • Equity market access: share price fell ~87% from the early-2026 high (~A$1.77) to A$0.225, raising the cost of any future raise.
  • Partner-dependency risk: Rio Tinto and ARENA payments depend on milestones and on "sourcing remaining funding" for Zesty.
  • Magnesia competition and input costs from larger US magnesia producers and caustic-soda price swings.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
2025 (H1 CY)Leilac scales back US projects amid DOE funding review under the Trump administrationRemoves near-term US growth vector; cost containment
24 Jul 2025ARENA grant up to A$44.9m for the Zesty Demonstration Plant (conditional on matched funding)Largest non-dilutive award in Calix history
26 Aug 2025FY25 results: revenue and other income A$33.9m (+11%); product and services revenue A$28.2m (+17%); cash A$23.0m; ~18-month runwaySets FY26 priorities (lithium plant, Zesty, Leilac-2, ZETA)
3 Sep 2025Services agreement with Norsk Hydro for low-emissions aluminaNew end market; revenue-generating testing
22 Sep 2025AGM date announcedProcedural
26 Sep 2025Project ZETA passes pre-FEED milestoneLime/CCU in SA progresses; later delayed
14 Oct 2025October newsletterShareholder communication
17 Oct 20252025 Notice of AGMCEO equity and NED share-in-lieu resolutions
21 Oct 2025Presentation at 14th Australian Microcap ConferenceInvestor outreach
29 Oct 2025Quotation and unquoted securities noticesEmployee equity scheme
17 Nov 2025Rio Tinto JDA (>A$35m) for the Zesty Green Iron Demo PlantMajor validation; shares up as much as 30% intraday to A$0.605 (Reuters)
18 Nov 20252025 AGM — all resolutions carried; remuneration report 89.65% forGovernance stability
4–5 Dec 2025Proposed issue / quotation of securities (NED shares in lieu of fees)Minor dilution
15 Dec 2025Rio Tinto completes due diligence; A$3m first paymentMoves Zesty into detailed design; FID targeted 2026
19 Dec 2025New US water-treatment contract worth up to A$10m a yearCould lift Magnesia revenue by ~40% at full run-rate
23 Dec 2025Lithium Mid-Stream Demo Plant construction complete, on budgetFirst commercial-scale electric plant
2 Jan 2026Response to ASX price query (stock ~A$1.145)Speculative rally; stock reached ~A$1.77 in early 2026
22 Jan 2026Frontier selects Leilac for zero-carbon lime (Google, Stripe, Shopify)Entry into the CDR buyer ecosystem
19 Feb 2026PLS–Calix revised Mid-Stream structure: A$11.4m for Calix's interestCapital release, but implies a A$30.2m write-down
24 Feb 20261H FY26 results: revenue +21%; Magnesia +48%; opex -30%; net loss A$42.8m incl impairment; Leilac-2 timing "unclear"Stock fell from ~A$1.59 (19 Feb) to ~A$1.01 at release
Feb 2026Bank of America facility replaces Columbia Bank lineUS working capital
10 Mar 2026Added to S&P/ASX All Ordinaries (effective 23 Mar 2026)Index inclusion after the early-2026 rally
16 Mar 2026First ARENA Zesty milestone met; A$2m cashGrant drawdown begins (A$42.9m remaining)
25 Mar 2026ASX SMIDcaps Conference presentationInvestor outreach
Apr 2026Unquoted securities notices (9, 16, 22 Apr)Employee equity incentives
18 Apr 2026Reuters: US DOE restores funding to carbon removal projects (relevant to Project Cypress)No follow-on from Heirloom for Leilac
20 Apr 2026PLS restructure executed; first A$5.7m; commissioning of Mid-Stream plant beginsLiquidity improvement
Jun 2026Hydro paid pilot testing using Alunorte feedstock completedAlumina pathway advances
16 Jun 2026Application for quotation of securitiesMinor
23 Jun 2026Leilac–Ambuja Cements JDA for a commercial-scale project, IndiaFirst customer-funded commercial cement pathway
29 Jun 2026East Asia cement contract; Leilac strategic review; Leilac-2, ZETA and US projects de-prioritised; Heirloom exclusivity removedStrategic pivot; flagship European demo effectively shelved
20 Jul 2026Proposed issue of securities (nature not detailed in sources reviewed)Monitor for dilution
22 Jul 2026July newsletterCommunication
31 Jul 2026Second and final A$5.7m PLS payment receivedPro-forma cash ~A$15.5m
4 Aug 2026FY26 results date and webinar announcedProcedural
26 Aug 2026FY26 results: record revenue A$36.0m; cash A$9.8m; CY26 cash-neutral guidance reiteratedStock ~A$0.23–0.30
8 Oct 2026Share price A$0.225Near multi-year lows; market cap ~A$49m

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

6 charts
Income Statement: Revenue & Gross Profit: Revenue rose from AUD 18.5 Mn in FY2022 to AUD 36 Mn in FY2026.
Calix Limited — Income Statement: Revenue & Gross Profit
Series (AUD Mn)FY2022FY2023FY2024FY2025FY2026
Revenue18.518.624.228.236
Cost of revenue13.312.413.917.521.8
Gross profit5.26.210.310.714.2

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. 1Calix ASX Announcement — "Calix FY26 Results: Record revenue and disciplined execution…" (bulletin.webull.com mirror of ASX PDF) — 26 Aug 2026 — FY26 financials, milestones, outlook
  2. 2Calix Interim Financial Report for the period ended 31 Dec 2025 ( — 24 Feb 2026 — Statements, segments, geography, going concern, directors, auditor (announcements.asx.com.au)
  3. 3Calix ASX Announcement — "Calix achieves 21% revenue growth…" (1H FY26) — 24 Feb 2026 — 1H highlights, Leilac-2 status
  4. 4Calix ASX Announcement — "Leilac secures contract with East Asian cement producer and prioritises zero capex commercial deployment" — 29 Jun 2026 — Leilac reprioritisation
  5. 5Calix FY25 Results and Investor Presentation (investorpa.com summaries) — 26 Aug 2025 — FY25 metrics
  6. 6Calix Appendix 4E FY23 ( — 24 Aug 2023 — FY23 results (announcements.asx.com.au)
  7. 7Calix Appendix 4E FY20 ( — 27 Aug 2020 — IER acquisition date (asx.com.au)
  8. 8Calix ASX Announcement — Leilac-2 relocation ( — 29 Jan 2024 — Leilac-2 history (announcements.asx.com.au)
  9. 9Calix 2025 AGM Notice and Results of Meeting (asxpdf/20251017; asxpdf/20251118) — Oct–Nov 2025 — Governance and votes
  10. 10Calix 2024 AGM Notice (asxpdf/20241022) — Oct 2024 — Board elections
  11. 11StockAnalysis.com (S&P Global Market Intelligence) — income statement, balance sheet, cash flow, statistics — Accessed Oct 2026 — 5-year financials, ratios, price
  12. 12InvestSMART — CXL announcements and price-sensitive summaries — 2025–2026 — Newsflow, release-day prices
  13. 13Simply Wall St — CXL ownership and management — 2025–2026 — Shareholders, CEO pay
  14. 14Market Index — director Catriona (Alison) Deans profile — 2025 — Board details
  15. 15Karoon Energy — Peter Turnbull biography — 2024 — Chair tenure
  16. 16Global Cement; Australian Manufacturing; CemNet — 2023–2024 — Leilac-2 JV and relocation
  17. 17ESD News; ProcessOnline; Energy Industry Review — Sep 2021 — Carbon Direct investment
  18. 18Finance News Network — 11 Dec 2019 — IER acquisition
  19. 19Reuters via Stockopedia — "Australia's Calix rises on Rio Tinto deal" — 17 Nov 2025 — Share reaction
  20. 20SmallCaps.com.au — CXL quote page — Early 2026 — 52-week range
  21. 21TipRanks — Leilac US project pause; substantial holder notice — 2025 — US projects; Thorney/TIGA
  22. 22Investing.com — Calix Ltd profile — 2026 — Employees, market cap
  23. 23Yahoo Finance (IT) / Statbase — Calix profile — 2025–2026 — HQ address, executives
  24. 24Wikipedia — Calix Limited — Accessed 2026 — Early history (founding, pilot calciner)
  25. 25GlobalData — Calix executives — 2025 — Chair since 2024
  26. 26financialfilings.com — Calix filings — 2026 — ISIN, LEI, IPO date

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.